2019
Expression of the type 3 InsP3 receptor is a final common event in the development of hepatocellular carcinoma
Guerra MT, Florentino RM, Franca A, Lima Filho AC, Dos Santos ML, Fonseca RC, Lemos FO, Fonseca MC, Kruglov E, Mennone A, Njei B, Gibson J, Guan F, Cheng YC, Ananthanarayanan M, Gu J, Jiang J, Zhao H, Lima CX, Vidigal PT, Oliveira AG, Nathanson MH, Leite MF. Expression of the type 3 InsP3 receptor is a final common event in the development of hepatocellular carcinoma. Gut 2019, 68: 1676. PMID: 31315892, PMCID: PMC7087395, DOI: 10.1136/gutjnl-2018-317811.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnimalsApoptosisCalcium SignalingCarcinogenesisCarcinoma, HepatocellularCell ProliferationCells, CulturedDNA MethylationFemaleGene Expression Regulation, NeoplasticHepatocytesHumansInositol 1,4,5-Trisphosphate ReceptorsLiverLiver NeoplasmsLiver RegenerationMaleMice, KnockoutMiddle AgedSurvival AnalysisConceptsChronic liver diseaseITPR3 expressionLiver cancer cellsLiver diseaseMouse modelFinal common eventCancer cellsSpecimens of patientsIndependent patient cohortsControl liver specimensHuman HCC cellsType 3 InsP3 receptorHuman liver samplesIncreased expression levelCancer deathPatient cohortCommon molecular eventPoor survivalHepatocellular carcinomaLiver specimensNormal liverHCC cellsAbstractTextHCCType 3 isoform
2018
Bariatric Surgery and Hepatocellular Carcinoma: a Propensity Score-Matched Analysis
Njei B, McCarty TR, Sharma P, Lange A, Najafian N, Ngu JN, Ngomba VE, Echouffo-Tcheugui JB. Bariatric Surgery and Hepatocellular Carcinoma: a Propensity Score-Matched Analysis. Obesity Surgery 2018, 28: 3880-3889. PMID: 30069863, PMCID: PMC6219901, DOI: 10.1007/s11695-018-3431-5.Peer-Reviewed Original ResearchConceptsBariatric surgeryHepatocellular carcinomaPrevalence ratiosOdds ratioLow prevalenceUnited States Nationwide Inpatient Sample databaseNationwide Inpatient Sample databaseOccurrence of HCCPropensity scorePrior bariatric surgeryHospital mortality rateMorbidly obese patientsAge-adjusted prevalenceMortality odds ratioRisk of deathLength of stayCross-sectional associationsHospital mortalityMorbid obesityBaseline characteristicsObese patientsSecondary outcomesBackgroundThe associationPrimary outcomePatient mortality
2017
Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non‐alcoholic fatty liver disease
Wong CR, Njei B, Nguyen MH, Nguyen A, Lim JK. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non‐alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics 2017, 46: 1061-1069. PMID: 28960360, DOI: 10.1111/apt.14342.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseFatty liver diseaseLarger tumor sizeLiver diseaseHCC etiologyCurative intentNAFLD-HCCCurative treatmentTumor sizeMetastatic HCCCardiovascular diseaseHepatocellular carcinomaDecompensated liver diseaseWorse median survivalAbsence of cirrhosisSignificant survival differenceDiagnosis of HCCLess cirrhosisNAFLD groupMedian survivalWorse survivalFavorable survivalIndependent predictorsLiver cirrhosisHCC group
2015
Emerging trends in hepatocellular carcinoma incidence and mortality
Njei B, Rotman Y, Ditah I, Lim JK. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology 2015, 61: 191-199. PMID: 25142309, PMCID: PMC4823645, DOI: 10.1002/hep.27388.Peer-Reviewed Original ResearchConceptsIB mortalityHCC incidenceHepatocellular carcinomaIncidence of HCCMultivariable Cox regression analysisOverall median survivalCox regression analysisEnd Results (SEER) dataSignificant survival improvementAge-adjusted incidenceU.S. populationHepatocellular carcinoma incidenceJoinpoint Regression ProgramIncidence-based mortalityRegression analysisSignificant increaseCurative modalityLiver transplantCurative stageMedian survivalSurvival improvementCarcinoma incidenceTumor sizeVascular invasionPrimary tumor
2014
Long-term Survival of Fibrolamellar Hepatocellular Carcinoma Versus Conventional Hepatocellular Carcinoma
Njei B. Long-term Survival of Fibrolamellar Hepatocellular Carcinoma Versus Conventional Hepatocellular Carcinoma. Journal Of Clinical Gastroenterology 2014, 48: 385-386. PMID: 24440939, PMCID: PMC4822547, DOI: 10.1097/mcg.0000000000000070.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaConventional hepatocellular carcinomaFibrolamellar hepatocellular carcinomaLong-term survivalPrognosis of Patients With Fibrolamellar Hepatocellular Carcinoma Versus Conventional Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
Njei B, Konjeti VR, Ditah I. Prognosis of Patients With Fibrolamellar Hepatocellular Carcinoma Versus Conventional Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Gastrointestinal Cancer Research : GCR 2014, 7: 49-54. PMID: 24799971, PMCID: PMC4007676.Peer-Reviewed Original ResearchMean overall survivalOverall survivalFL-HCCHepatocellular carcinomaNoncirrhotic patientsSystematic reviewConventional HCCPrognosis of patientsConventional hepatocellular carcinomaFibrolamellar hepatocellular carcinomaRandom-effects modelOutcomes of interestSignificant increaseTypes of HCCLiver transplantationFibrolamellar variantHepatic resectionBetter prognosisClinical courseSurvival outcomesTherapeutic optionsCochrane LibrarySubgroup analysisEgger's testRevMan 5.1
2013
Persistent racial disparities in survival among u.s. Adults with hepatocellular carcinoma after liver transplantation: the paradox of all-cause and cause-specific mortality.
Njei B, Ditah I, Lim JK. Persistent racial disparities in survival among u.s. Adults with hepatocellular carcinoma after liver transplantation: the paradox of all-cause and cause-specific mortality. Gastrointestinal Cancer Research : GCR 2013, 6: 73-4. PMID: 23936546, PMCID: PMC3737508.Peer-Reviewed Original Research